Seattle biotech startup Outpace Bio raises $30M to fight cancer with custom-designed proteins
Outpace Bio, a biotech company based in Seattle, announced it has raised $30M in a Series A round, led by ARTIS Ventures and Lyell. Outpace, which researchers T-cell therapies, also announced a partnership with Lyell Immunopharma to explore commercializing a potential immune cell therapy for cancer treatment.
In a statement to GeekWire Lajoie said, “A biological activity that is beneficial in one context can drive dysfunction or toxicity in another. Outpace is working to overcome this by reprogramming cells to make the right decisions in the right context. We believe that cures will require the full power of cells to intervene in complex biology in ways that small molecule drugs and biologics cannot.”